Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eczema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    341 result(s) found for: eczema. Displaying page 11 of 18.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2006-000292-15 Sponsor Protocol Number: S241-GB-10 Start Date*: 2006-03-13
    Sponsor Name:Stiefel Laboratories Maidenhead Ltd.
    Full Title: A Phase II, Single-Centre, Randomised,Double-Blind, Parallel Group, CPO Solution, Dose Range Finding Study in Subjects with Seborrhoeic Dermatitis of the Scalp
    Medical condition: Seborrhoeic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039793 Seborrhoeic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002060-26 Sponsor Protocol Number: 1401201 Start Date*: 2006-12-04
    Sponsor Name:Intendis GmbH
    Full Title: A double-blind, randomized, vehicle-controlled, 6-week exploratory multicenter pilot study of the efficacy and safety of Azelaic Acid (AzA) 15% gel in the topical treatment of mild to moderate seb...
    Medical condition: Patients with mild to moderate seborrheic dermatitis of the facial area and meeting the specific eligibility criteria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012488 Dermatitis seborrheic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000720-19 Sponsor Protocol Number: IDI01/2020 Start Date*: 2020-07-22
    Sponsor Name:IDI FARMACEUTICI SRL
    Full Title: A prospective, randomized, multicenter, open- label, two-arm and parallel-group Study to evaluate the efficacy and safety of Nicotinamide DS compared to Ciclopirox olamine cream at 1% in patients a...
    Medical condition: Patients affected by seborrheic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10039793 Seborrhoeic dermatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003106-41 Sponsor Protocol Number: CHDR1733 Start Date*: 2018-09-05
    Sponsor Name:Maruho Co., Ltd.
    Full Title: A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to ...
    Medical condition: Mild to moderate facial seborrheic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10039788 Seborrheic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002771-33 Sponsor Protocol Number: ATX201-207 Start Date*: 2019-09-25
    Sponsor Name:UNION therapeutics A/S
    Full Title: A Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults with Mild to Moderate Atopic De...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003712-45 Sponsor Protocol Number: INCB18424-303 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic ...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003713-18 Sponsor Protocol Number: INCB18424-304 Start Date*: Information not available in EudraCT
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic ...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BG (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004184-79 Sponsor Protocol Number: NIAD-01 Start Date*: 2013-05-01
    Sponsor Name:Dermal Laboratories Limited
    Full Title: A placebo controlled evaluation of a developmental gel for the treatment of atopic eczema
    Medical condition: The medical condition to be investigated in this study is atopic eczema, also known as atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003641 Atopic eczema LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002351-16 Sponsor Protocol Number: AP-CL-ECZ-PI-006539 Start Date*: 2017-05-10
    Sponsor Name:Technische Universität München, Fakultät für Medizin, represented by Dean
    Full Title: An investigator-initiated, randomized, double-blind, placebo controlled study of Apremilast to demonstrate efficacy in subjects with nummular eczema
    Medical condition: Nummular Ecema is an idiopathic chronic inflammatory skin disease that occurs throughout all life periods. Diagnose is made primarily clinically in correlation with histological findings. Treatment...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10014201 Eczema nummular PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003543-16 Sponsor Protocol Number: LP0133-1528 Start Date*: 2022-07-28
    Sponsor Name:LEO Pharma A/S
    Full Title: A 24 week, randomised, assessor blinded, active-controlled, parallel group, phase 3, 2 arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsu...
    Medical condition: Chronic Hand Eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Ongoing) FR (Completed) AT (Completed) PL (Completed) NO (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003140-56 Sponsor Protocol Number: D200 Probørn Start Date*: 2006-02-10
    Sponsor Name:Department of Human Nutrition, The Royal Veterinary and Agricultural University
    Full Title: Probiotics to infants with atopic dermatitis; an investigation of the effect on eczema, immune system and intestinal microflora, inflammation and permeability. DK-titel Probiotiske bakterier til ...
    Medical condition: Infants participating in the clinical trial are suffering from atopic dermatitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006340-27 Sponsor Protocol Number: LP0133-1426 Start Date*: 2022-04-21
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to evaluate efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adolescents 12-17 ye...
    Medical condition: Chronic Hand Eczema
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004858 10084778 Chronic hand eczema LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002176-75 Sponsor Protocol Number: CZPL389A2203 Start Date*: 2019-11-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) FI (Prematurely Ended) IS (Completed) AT (Prematurely Ended) EE (Prematurely Ended) BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002401-56 Sponsor Protocol Number: I9N-MC-FCAB Start Date*: 2019-04-29
    Sponsor Name:Eli Lilly & Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006844-21 Sponsor Protocol Number: DELP-01 Start Date*: 2009-12-01
    Sponsor Name:Dermal Laboratories Ltd
    Full Title: Evaluation of a developmental ‘long lasting’ emollient in subjects with dry skin.
    Medical condition: Eczema sufferers with dry skin.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012435 Dermatitis and eczema HLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001136-21 Sponsor Protocol Number: B7451013 Start Date*: 2018-10-22
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of PF-04965842 Monotherapy in Subjects Aged 12 Years and Older, with M...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) CZ (Completed) GB (Completed) DE (Completed) PL (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2016-001505-17 Sponsor Protocol Number: BILA-3716/PRU Start Date*: 2016-07-29
    Sponsor Name:FAES FARMA, S.A.
    Full Title: An exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases.
    Medical condition: Chronic spontaneous urticaria and the following skin disorders: 1 - Eczema/dermatitis (acute eczema, chronic eczema, contact dermatitis, atopic dermatitis, nummular eczema, autosensitisation dermat...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10012435 Dermatitis and eczema HLT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
    19.0 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-004649-14 Sponsor Protocol Number: ASF-1057-303 Start Date*: 2008-02-19
    Sponsor Name:Astion Pharma A/S
    Full Title: Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial
    Medical condition: Seborrhoeic dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004705-26 Sponsor Protocol Number: LPS15497 Start Date*: 2020-03-24
    Sponsor Name:Sanofi Aventis Groupe
    Full Title: A randomized double blind placebo controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004308-11 Sponsor Protocol Number: GTG002.07 Start Date*: 2010-01-11
    Sponsor Name:Genethon
    Full Title: PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME
    Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopenia,...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10047992 Wiskott-Aldrich syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 19 08:12:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA